ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INDP
MNPR (27) PHAT (33) FTH (28) EOLS (26) ⌘ Pro Terminal →

Indaptus Therapeutics Inc. (INDP) — RQD Stock Rating Cockpit

$3.50 +13.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.58

Indaptus Therapeutics Inc. (INDP) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $474.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INDP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Indaptus Therapeutics Inc. (NASDAQ: INDP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $3.50 (+13.27% 1D, market cap $474.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, INDP ranks #421 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INDP compare to MNPR and PHAT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INDP carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MNPR (Monopar Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $472.0M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $466.6M). Among the 5-stock peer group, INDP leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INDP?
▼

Per INDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001857044), Indaptus Therapeutics Inc. generated $55.5M in revenue (+29.1% YoY), -$20.8M in net income, and -$14.8M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.58 (+2.20%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (7)Whales (11)SEC (10)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.1% Base Target
$6 Bull$3 Base$3 Bear
📬 FREE INDP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INDP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY INDP SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 51% of 52W Range • RSI-14 at 53.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$2.39+23.8% Next Q
Q2 (-2Q)
37
Grade E$2.96+11.8% Next Q
Q3 (-1Q)
39
Grade E$3.31+5.7% Next Q
Current
42
Grade D-$3.50-7% Hist 90D α
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INDP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INDP currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.63) and Max Pain ($3.68) forces dealer call-delta covering toward $6.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INDP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INDP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
53.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE51% OF RANGE
L: $1$3.50H: $6
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on INDP

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -2.89% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (42)

14/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like INDP
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INDP)

  • ✓Walkthrough of INDP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INDP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +62.79%⚡ TESTING RESISTANCE
2026-11-03O $3.34H $3.50L $3.09C $3.50VOL 241.9K
RES: $3.91SUP: $0.92SMA50: $2.63SMA200: $2.29
$6.31$4.85$3.39$1.93$0.47RES $3.91SUP $0.92$3.502026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INDP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INDP Butterfly Map → + Track INDP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +29.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INDP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INDP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INDP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INDP)

Health Care Rank #421 of 1015 ⚔️ MNPR vs INDP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INDP vs. MNPR, PHAT, FTH, EOLS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Indaptus Therapeutics Inc. (INDP) ranks #421 by composite RQD confidence (42/100, grade D-) and #453 by equity capitalization ($474.6M). Within this direct 5-issuer industry benchmark cohort, INDP leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. INDP currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INDP ACTIVE
Indaptus Therapeutics Inc.
D- 42/100 — — -35.0% +13.27% $474.6M Benchmark Subject
MNPR
Monopar Therapeutics Inc.
E 27/100 — — -17.4% -5.74% $472.0M /mnpr-vs-indp →
PHAT
Phathom Pharmaceuticals Inc.
E 33/100 — 87.1% -35.0% +3.05% $466.6M /phat-vs-indp →
FTH
Faeth Therapeutics Inc.
E 28/100 — — -35.0% +2.89% $483.0M /fth-vs-indp →
EOLS
Evolus Inc.
E 26/100 — 66.3% -35.0% -2.58% $485.5M /eols-vs-indp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001857044 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Indaptus Therapeutics Inc. (INDP) reported GAAP revenue of $55.5M (+29.1% vs. FY2024 revenue of $43.0M , and +21.1% cumulative change since FY2023) , GAAP net income of -$20.8M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (-20.3% YoY). On the balance sheet, INDP closed FY2025 with $9.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $55.5M -$20.8M -$14.8M -$14.8M $9.3M —
FY2024 (FY) 2024-12-31 $43.0M -$15.0M -$12.3M -$12.3M $7.3M —
FY2023 (FY) 2023-12-31 $45.9M -$15.4M -$13.4M -$13.4M — —

3. INDP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Indaptus Therapeutics Inc. (NASDAQ: INDP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $3.50 (+13.27% 1D, market cap $474.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, INDP ranks #421 in composite RQD confidence.

How does INDP compare to MNPR and PHAT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INDP carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MNPR (Monopar Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $472.0M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $466.6M). Among the 5-stock peer group, INDP leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INDP?

Per INDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001857044), Indaptus Therapeutics Inc. generated $55.5M in revenue (+29.1% YoY), -$20.8M in net income, and -$14.8M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INDP trading relative to its 50-day, 200-day, and 52-week technical levels?

INDP last traded at $3.50 (+13.27% on volume of 226,228 shares), positioning the stock +33.08% above its 50-day simple moving average ($2.63) and +52.84% above its 200-day simple moving average ($2.29). Across its 52-week range of $0.92 to $5.96, INDP sits at the 51.2% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.06 to $3.94).

Direct Sub-Reports: INDP RQD Cockpit INDP 12M Forecast INDP Earnings & Move INDP Dividends & DRIP INDP Insiders & 13F INDP Whale Options INDP Profit Sankey INDP News & Why
ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ SEC XBRL & RQD VERIFIED

INDP — Indaptus Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Indaptus Therapeutics Inc. (INDP) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.50 (+13.27% 1D, market capitalization $474.6M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -2.89%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Indaptus Therapeutics Inc. (INDP) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company has a market capitalization of $0.5B. The reported revenue of — across all three fiscal years is consistent with a pre-revenue profile, though the source does not state this explicitly.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Indaptus Therapeutics Inc. (INDP) reported $55.5M in annual revenue (up from $43.0M in FY2024, +29.1% YoY) and -$20.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($45.9M revenue, -$15.4M net income) through FY2025, INDP scaled operating cash flow to -$14.8M and free cash flow to -$14.8M, backed by $9.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.89% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.92 – $5.96 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be assessed from the source data. Sector correlation is limited to the beta of 1.0 and the Health Care classification. A second-order item to monitor is the dilutive effect of equity financing on per-share metrics, given the completed $24 million private placement and the absence of reported EPS.

  • Key Question #1: Can INDP sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $55.5M and free cash flow of -$14.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is INDP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INDP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Indaptus Therapeutics Inc. (INDP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INDP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INDP Bull vs. Bear Conversation Board — What's Your Call at $3.50?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INDP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INDP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $4.05 (+31.1%)
📌 Pinned Debate

Institutional accumulation and options positioning score 13 / 20 and the stock recovered sharply after the Q4 2025 earnings report, per

Don't sleep on INDP's setup in Health Care. Institutional accumulation and options positioning score 13 / 20 and the stock recovered sharply after the Q4 2025 earnings report, per the source headlines.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (42/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — INDP's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $2.63 (-14.9%)
Spot @ $3.09

ROIC of -35%, negative free cash flow in every reported period, and an insider conviction score of 3 / 20 signal a cash-consuming busin

Fading this rally in INDP at $3.09. ROIC of -35%, negative free cash flow in every reported period, and an insider conviction score of 3 / 20 signal a cash-consuming business with little insider support.. With a beta of 1.0 and the stock sitting at $3.09 (52-wk range $0.92–$5.96), the easy multiple expansion is already priced in.

LIVE TAPE